Make the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab
Copies of the big antibody drugs are approved and cheaper, but uptake depends on each prescriber; letting the pharmacy substitute the biosimilar unless the oncologist objects would move most patients within a year.
Overview
FDA-approved biosimilars of trastuzumab, bevacizumab, rituximab and pegfilgrastim have been on the US market since 2019. IQVIA estimated that biosimilars saved $56 billion over the decade to 2022 and projected $181 billion more over 2023 to 2027. Uptake still varies widely by practice because substitution requires a prescriber decision, a payer preference and a purchasing contract to line up. A default-substitution rule (opt-out rather than opt-in), combined with the flat-fee payment idea, removes the friction. NHS England and several European systems achieved over 90% uptake this way.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Knowledge reaches practice too slowly · Knowledge diffusion is slow: it takes years for a proven result to change what most patients receive, and no one can keep up with the literature.
Pages like this
not linked directly; found by shared links- CompanyHetero Drugs
Shares Biosimilar, Rituximab, Bevacizumab, Prices and value.
- CompanyBiocon Biologics
Shares Trastuzumab biosimilars, Biosimilar, Bevacizumab, Trastuzumab.
- CompanyBiocon
Shares Trastuzumab biosimilars, Biosimilar, Bevacizumab, Trastuzumab.
- CompanyIntas Pharmaceuticals (Accord Healthcare)
Shares Biosimilar, Prices and value.
- CompanyDr. Reddy's Laboratories
Shares Biosimilar, Rituximab, Prices and value.
- IdeaBiosimilar-first defaults and payment parity in every cancer day unit
Shares Trastuzumab, Prices and value.
- IdeaDrop the extra switching studies for interchangeable oncology biosimilars
Shares Biosimilar, Prices and value.
- IdeaPay a flat fee for giving a Part B drug instead of 6% of its price
Shares Biosimilar, Prices and value.